普拉瓦斯塔丁可以减少马尔凡大动脉扩张
Darren McLoughlin1, Jonathan McGuinness, John Byrne
1Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
Circulation
|September 14, 2011
概括
类药物和洛萨坦药物通过保留弹性质和减少血管光滑肌细胞中的蛋白质合成,有效地降低了马尔凡综合征小鼠中的大动脉根扩张.
科学领域:
- 心血管研究研究心血管研究
- 遗传学与疾病的关系
- 药理学 药理学是指药理学的学科.
背景情况:
- 马方综合征的特征是由于矩阵元素失衡和过度的TGF-β信号传递而导致致命的大动脉根扩张.
- 这种不平衡导致大动脉中介层金属蛋白酶活性增加.
研究的目的:
- 在马方综合征小鼠模型中研究他类药物减轻大动脉根扩张的疗效.
- 为了比较他类药物的效果与另一种建议的预防剂洛萨坦,另一种建议的预防剂.
主要方法:
- 马尔凡小鼠 (C1039G 纤维素-1 突变) 从 6 周大以后接受了普拉瓦斯塔丁或洛萨坦治疗.
- 分析了大动脉根的直径,厚度,弹性质体积,心脏功能 (dp/dtmax) 和超结构.
主要成果:
- 与未经治疗的对照相比,普拉瓦斯塔丁和洛萨坦在马尔凡小鼠中显著降低了大动脉根扩张.
- 这两种药物都保持了中间层弹性质体积,并减少了光滑肌细胞中的粗的内质网膜,表明蛋白质合成减少.
结论:
- 在马方综合征小鼠模型中,他类药物在减轻大动脉根扩张方面表现出与洛萨坦相似的疗效.
- 类他类药物可能通过减少血管光滑肌细胞过度蛋白质产生来提供临床上有用的,耐受性良好的长期治疗选择.
相关概念视频
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Aneurysm I: Introduction
An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...


